Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LNS 8801

Next Previous
Drug Profile

LNS 8801

Alternative Names: GPER agonist - Linnaeus Therapeutics; LNS-8801

Latest Information Update: 08 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Linnaeus Therapeutics
  • Developer Linnaeus Therapeutics; Merck Sharp & Dohme
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Estrogen receptor agonists; G protein-coupled receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveal melanoma; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Lymphoma; Malignant melanoma; Solid tumours
  • Preclinical Uveal melanoma
  • No development reported Pancreatic cancer

Most Recent Events

  • 26 Mar 2025 Linnaeus Therapeutics plans a phase I/II trial in Malignant melanoma (Monotherapy, Metastatic disease, Combination therapy, Second-line therapy or later, Inoperable/Unresectable) in USA, in the second quarter of 2025 (NCT06624644)
  • 16 Sep 2024 Efficacy and adverse event data from a phase I/II trial in Malignant melanoma released by Linnaeus Therapeutics
  • 13 Sep 2024 Efficacy and adverse event data from a phase I/II trial in Malignant melanoma presented at 49th European Society for Medical Oncology Congress (ESMO-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top